GlobalData on MSN6d
Palatin concludes Phase II trial of combination therapy for obesity
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
Yahoo Finance1mon
Palatin reports positive Phase 2b results in diabetic nephropathy
Palatin (PTN) announced topline data for the BREAKOUT study, a Phase IIb study of bremelanotide in diabetic kidney disease. The study showed that bremelanotide therapy for six months, in patients ...
Morningstar8d
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...
Nasdaq7d
Palatin Technologies Completes Phase 2 Obesity Study On MC4R Bremelanotide And Tirzepatide
The study's primary endpoint was to evaluate the efficacy of bremelanotide combined with tirzepatide in reducing body weight. Data from this trial are expected later this quarter. The results from ...
Finanznachrichten7d
Palatin Technologies, Inc.: Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...